Agilon Health (NYSE:AGL) Director John William Wulf Purchases 81,000 Shares of Stock

Agilon Health, Inc. (NYSE:AGL) Director John William Wulf acquired 81,000 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were acquired at an average price of $0.63 per share, with a total value of $51,030.00. Following the acquisition, the director owned 365,857 shares in the company, valued at approximately $230,489.91. The trade was a 28.44% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Agilon Health Price Performance

Shares of NYSE:AGL opened at $0.84 on Friday. The business’s 50-day moving average is $0.78 and its 200 day moving average is $1.03. Agilon Health, Inc. has a 1 year low of $0.51 and a 1 year high of $6.08. The firm has a market capitalization of $346.22 million, a P/E ratio of -1.11 and a beta of 0.05.

Agilon Health (NYSE:AGL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.09). Agilon Health had a negative return on equity of 75.92% and a negative net margin of 5.24%.The business had revenue of $1.44 billion during the quarter, compared to analyst estimates of $1.43 billion. On average, analysts expect that Agilon Health, Inc. will post -0.59 EPS for the current year.

Institutional Trading of Agilon Health

A number of hedge funds have recently modified their holdings of the stock. Signaturefd LLC increased its stake in shares of Agilon Health by 65.1% in the 2nd quarter. Signaturefd LLC now owns 30,479 shares of the company’s stock valued at $70,000 after purchasing an additional 12,018 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Agilon Health by 1,028.9% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 789,703 shares of the company’s stock valued at $1,816,000 after purchasing an additional 719,751 shares during the period. Geode Capital Management LLC increased its position in shares of Agilon Health by 2.6% in the second quarter. Geode Capital Management LLC now owns 7,156,466 shares of the company’s stock valued at $16,462,000 after buying an additional 178,477 shares in the last quarter. XTX Topco Ltd raised its stake in shares of Agilon Health by 583.2% during the 2nd quarter. XTX Topco Ltd now owns 400,760 shares of the company’s stock worth $922,000 after buying an additional 342,100 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of Agilon Health by 60.1% during the 2nd quarter. SG Americas Securities LLC now owns 230,912 shares of the company’s stock valued at $531,000 after buying an additional 86,723 shares in the last quarter.

Analysts Set New Price Targets

AGL has been the topic of a number of research analyst reports. Wells Fargo & Company dropped their price objective on shares of Agilon Health from $1.50 to $1.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Zacks Research raised Agilon Health from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 21st. BTIG Research reissued a “neutral” rating on shares of Agilon Health in a report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agilon Health in a report on Wednesday, January 21st. Finally, Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, December 3rd. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $2.71.

Trending Headlines about Agilon Health

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Agilon director John William Wulf bought 81,000 AGL shares (avg. $0.63) in November, increasing his stake by ~28%—an insider purchase investors often view as a sign of confidence. Insider Form 4
• Neutral Sentiment: Brokerage consensus remains lukewarm: recent coverage shows an average recommendation of “Hold,” suggesting analysts are cautious but not uniformly bearish. Analyst Consensus
• Negative Sentiment: Bronstein, Gewirtz & Grossman filed/urged investors to act in a class action alleging investor harm against Agilon and certain officers—adds to legal exposure and headline risk. Bronstein, Gewirtz & Grossman filing
• Negative Sentiment: Faruqi & Faruqi says it is investigating claims on behalf of Agilon investors and is soliciting potential class members—more counsel activity increases likelihood of consolidated litigation and potential discovery/settlement costs. Faruqi & Faruqi notice
• Negative Sentiment: Multiple other plaintiff firms (Rosen, Levi & Korsinsky, Bernstein Liebhard, Pomerantz, The Gross Law Firm) have filed or issued shareholder alerts reminding investors of lead‑plaintiff deadlines—this sustained outreach keeps Agilon in the legal headlines and may pressure the stock. Rosen Law Firm notice Levi & Korsinsky notice Bernstein Liebhard notice Pomerantz notice The Gross Law Firm notice

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.